Surat Samachar

The Dry Eye Disease therapeutics landscape is anticipated to transform with the approval of pipeline therapies by key players including Ocugen, Novartis, HanAll Biopharma, and others

 Breaking News
  • No posts were found

The Dry Eye Disease therapeutics landscape is anticipated to transform with the approval of pipeline therapies by key players including Ocugen, Novartis, HanAll Biopharma, and others

August 26
14:00 2021
The Dry Eye Disease therapeutics landscape is anticipated to transform with the approval of pipeline therapies by key players including Ocugen, Novartis, HanAll Biopharma, and others
Dry Eye Disease Market
A number of approved therapies such as Xiidra and Cequa are driving the current Dry Eye Disease therapeutic landscape in the United States.

DelveInsight’s Dry Eye Disease market report provides an in-depth understanding of Dry Eye Disease, historical and forecasted epidemiology, as well as Dry Eye Disease market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). The report also discusses current Dry Eye Disease treatment practices/algorithms, Dry Eye Disease market drivers, Dry Eye Disease market barriers, and unmet medical needs. 

Some of the Key Highlights from the Dry Eye Disease Market Report

  • According to Dana et al., the overall Dry Eye Disease prevalence in 2019 was 5.28 percent and it is more common in females as compared to males in the US.

  • According to the Association of Optometrists, 1 out of every 4 people in the UK suffers from dry eye.

  • Oyster Point Pharma, Ocugen, HanAll Biopharma, mc2 therapeutics, Novartis, Novaliq, Aurinia Pharmaceuticals, Kala Pharmaceuticals, and others are among the key players that are diligently working towards the development of novel treatment options for Dry Eye Disease.

  • The emerging therapies in the Dry Eye Disease market include OC-01/OC-02, OCU 310, HMB9036, MC2-03, ECF843, Voclosporin ophthalmic solution, KPI-121, and several others.

  • NOV03 (100 percent perfluorohexyloctane) by Novaliq is the first drug developed to effectively treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction.

  • Oyster Point Pharma is working on a lead product candidate, OC-01, which is a highly selective nAChR agonist being developed for the treatment of Dry Eye Disease signs and symptoms.

  • Mc2 Therapeutics by using PAD Technology is developing MC2-03, a new cyclosporine eye drop that is designed to improve cyclosporine delivery into the eyes using a vehicle/eye drop that is highly tolerable.

Request for the sample to know more about the disease @ Dry Eye Disease Market Outlook

The Dry Eye Disease market report covers current treatment practices, emerging drugs, individual therapy Dry Eye Disease market share, current and forecasted Dry Eye Disease market Size from 2018 to 2030, segmented by seven major markets.

Dry Eye Disease: Overview

Dry Eye Disease (DED), also known as Dry Eye Syndrome (DES) or Keratoconjunctivitis Sicca (KCS), is a common condition in which the eyes produce insufficient tears or the tears evaporate too quickly. Because tears are required to lubricate and nourish the eye, the condition causes the eyes to dry out and become red, swollen, and irritated. Dry eye syndrome is caused by a chronic lack of lubrication and moisture on the surface of the eye. The consequences of dry eyes range from minor but persistent eye irritation to significant inflammation and even scarring of the eye’s front surface. It can affect one or both eyes and cause inflammation.

Dry Eye Disease Epidemiology Segmentation

The Dry Eye Disease report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Dry Eye Disease Total Prevalent Pool

  • Dry Eye Disease Total Diagnosed Cases

  • Dry Eye Disease Type-Specific Diagnosed Cases

  • Dry Eye Disease Severity-Specific Prevalent Pool

  • Dry Eye Disease Age-Specific Prevalent Pool

  • Dry Eye Disease Gender-Specific Prevalence

Dry Eye Disease Treatment Landscape

Keratoconjunctivitis is treated in a variety of ways. Dry Eye Disease treatment aims to alleviate dry eye symptoms, improve patient comfort, restore the ocular surface and tear film to normal, and, whenever possible, prevent corneal damage. Dry Eye Disease treatment options include education, environmental or dietary changes, artificial tear substitutes, punctual plugs, topical and/or systemic anti-inflammatory medications, and surgery. Along with this, some FDA-approved drugs are also used. Xiidra (lifitegrast ophthalmic solution) and Cequa (cyclosporine ophthalmic solution) are among the FDA-approved drugs used for Dye Eye Disease treatment. 

Dry Eye Disease Market

The current Dry Eye Disease therapeutic landscape in the United States is driven by a number of approved therapies. The Dry Eye Disease market is expected to expand by 2030. The launch of the most anticipated therapies such as OCU 310, HMB9036, MC2-03, ECF843, and others are the primary reason for the increase in the Dry Eye Disease market size.

Dry Eye Disease Pipeline Therapies and Key Companies 

  • OC-01/OC-02: Oyster Point Pharma

  • OCU 310: Ocugen

  • HMB9036: HanAll Biopharma

  • MC2-03: mc2 therapeutics

  • ECF843: Novartis

  • Voclosporin ophthalmic solution: Aurinia Pharmaceuticals

  • KPI-121: Kala Pharmaceuticals

  • NOV03: Novaliq

For more information on the current and emerging therapies of dry eye disease, visit Drugs for the Treatment of Dry Eye Disease 

Dry Eye Disease Market Drivers

  • Lack of approved therapies

  • Marketed delivery systems

  • Rising incidence of dry eye disease

  • High cost and patent expiry

Dry Eye Disease Market Barriers

  • Ineffective drug concentration

  • Membrane and dynamic barriers to drug permeability

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Dry Eye Disease Key Companies: Oyster Point Pharma, Ocugen, HanAll Biopharma, mc2 therapeutics, Novartis, Novaliq, Aurinia Pharmaceuticals, Kala Pharmaceuticals, among others. 

Dry Eye Disease Key Pipeline Therapies: OC-01/OC-02, OCU 310, HMB9036, MC2-03, ECF843, Voclosporin ophthalmic solution, KPI-121and others.

Dry Eye Disease Segmentation: By Geography, By Dry Eye Disease therapies

Analysis: Comparative and conjoint analysis of Dry Eye Disease emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

1.

Report Introduction

2.

Executive Summary

3.

Dry Eye Disease Market Overview at a Glance

4.

Dry Eye Disease: Disease Background and Overview

5.

Dry Eye Disease Epidemiology and Patient Population – 7MM

6.

Treatment and Management of Dry Eye Disease

7.

Dry Eye Disease Unmet Needs

8.

Dry Eye Disease Marketed Drugs

9.

Dry Eye Disease Emerging Therapies

10.

Dry Eye Disease: Market Analysis

11.

Dry Eye Disease Market Drivers

12.

Dry Eye Disease Market Barriers

13.

Appendix

14.

DelveInsight Capabilities

15.

Disclaimer

16.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Wet Age-Related Macular Degeneration Market

Get a comprehensive analysis of Wet Age-Related Macular Degeneration pipeline therapies and key companies such as Novartis, Pfizer, Roche, Opthea Limited, REGENXBIO, Clearside Biomedical, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles